BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 3007640)

  • 21. The clinical significance of pre-operative serum CA 125 in ovarian cancer.
    Cruickshank DJ; Fullerton WT; Klopper A
    Br J Obstet Gynaecol; 1987 Jul; 94(7):692-5. PubMed ID: 2441738
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Carcinoma of the ovary: reliability of its markers].
    Moggian G; Gunelli R; Magrone F; Canali P; Spadazzi AP; Pini PL
    Minerva Ginecol; 1988 Jan; 40(1):9-13. PubMed ID: 3163780
    [No Abstract]   [Full Text] [Related]  

  • 23. Clinical evaluation of circulating serum sialyl Tn antigen levels in patients with epithelial ovarian cancer.
    Kobayashi H; Terao T; Kawashima Y
    J Clin Oncol; 1991 Jun; 9(6):983-7. PubMed ID: 1851822
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical evaluation of a cancer antigen CA125 associated with ovarian cancer. (III) Serum CA125 levels in patients with ovarian cancer and other gynecological tumors].
    Suzuki M; Sekiguchi I; Tamada T; Sakurabayashi I; Kawai T
    Rinsho Byori; 1985 Feb; 33(2):173-7. PubMed ID: 3858562
    [No Abstract]   [Full Text] [Related]  

  • 25. [Clinical usefulness of monoclonal antibody, CA 125 and CA 19-9 in ovarian cancer].
    Saitoh S; Nakanishi A; Noda T; Ando Y; Katakami Y; Kiyozuka Y; Moriyama I; Ichijo M
    Nihon Gan Chiryo Gakkai Shi; 1984 Dec; 19(10):2327-35. PubMed ID: 6598184
    [No Abstract]   [Full Text] [Related]  

  • 26. [Relationship between serum CA125 level and second-look findings in ovarian cancers].
    Liu LY
    Zhonghua Zhong Liu Za Zhi; 1992 Jul; 14(4):287-9. PubMed ID: 1327702
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Predictive value of a tumor marker combination for the monitoring of ovarian cancer].
    Lahousen M
    Wien Klin Wochenschr; 1986 May; 98(10):319-25. PubMed ID: 3460273
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical correlations of ovarian cancer antigen NB/70K: a preliminary report.
    Dembo AJ; Chang PL; Urbach GI
    Obstet Gynecol; 1985 May; 65(5):710-4. PubMed ID: 3856794
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of CEA, CA125, CA19-9 and human milk fat globule membrane antigen in ovarian tumours.
    Macdonald F; Bird R; Stokes H; Russell B; Crocker J
    J Clin Pathol; 1988 Mar; 41(3):260-4. PubMed ID: 3162916
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor associated antigen in ovarian carcinoma.
    Negishi Y; Mutai Y; Akiya K; Fujiwara Y; Singh G
    Nihon Sanka Fujinka Gakkai Zasshi; 1984 Jan; 36(1):126-32. PubMed ID: 6199439
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Serum CA125 in malignant ovarian tumor--periodical monitoring and correlation with other tumor markers].
    Kawai M; Yamashita H; Hayashi T; Kamiya N; Kakihara M; Arii Y
    Nihon Sanka Fujinka Gakkai Zasshi; 1986 Mar; 38(3):402-10. PubMed ID: 3457877
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of human ovarian tumor-associated antigens by sandwich enzyme immunoassay.
    Rao GS; Hanjani P
    Obstet Gynecol; 1988 Mar; 71(3 Pt 1):423-8. PubMed ID: 3279355
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A monoclonal antibody radioimmunoassay for an antigenic determinant CA125 in ovarian cancer patients.
    Lian LJ; Hu XF; Liu WS; Wu AJ
    Chin Med J (Engl); 1986 Sep; 99(9):721-6. PubMed ID: 2433106
    [No Abstract]   [Full Text] [Related]  

  • 34. Serum and tissue measurements of CA72-4 in ovarian cancer patients.
    Negishi Y; Iwabuchi H; Sakunaga H; Sakamoto M; Okabe K; Sato H; Asano G
    Gynecol Oncol; 1993 Feb; 48(2):148-54. PubMed ID: 8381375
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [New prospects in the combined use of tumor markers in epithelial neoplasms of the ovary].
    Indraccolo SR; Cecchi A; Thodos A; Brandi S; Carta G
    Ann Ostet Ginecol Med Perinat; 1991; 112(1):36-40. PubMed ID: 1929097
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.
    Bast RC; Klug TL; St John E; Jenison E; Niloff JM; Lazarus H; Berkowitz RS; Leavitt T; Griffiths CT; Parker L; Zurawski VR; Knapp RC
    N Engl J Med; 1983 Oct; 309(15):883-7. PubMed ID: 6310399
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Serum levels of CA 125, CA 19-9, TPA, CEA and CA 50: useful evaluation parameters in the diagnosis of ovarian cancer].
    Gadducci A; Ferdeghini M; Bartolini T; Facchini V; Bianchi R; Fioretti P
    Ann Ostet Ginecol Med Perinat; 1986; 107(4):193-9. PubMed ID: 3467641
    [No Abstract]   [Full Text] [Related]  

  • 38. Density distribution and antigenic characterization of cell subpopulations isolated from cystic fluids of ovarian serous neoplasms.
    Harłozińska A; Bar JK; Rabczyński J; Noworolska A; Richter R; Cisło M
    Anticancer Res; 1989; 9(1):161-6. PubMed ID: 2705745
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Significance of CA 125 antigen levels in patients with ovarian cancer].
    Shimizu Y; Fujiwara H; Akagaki E; Hirota K; Kono M; Irie T; Miura S; Okudaira Y
    Gan To Kagaku Ryoho; 1986 Jan; 13(1):46-52. PubMed ID: 3455806
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ovarian tumor antigens: preliminary histological investigation.
    Daunter B; Jaa-Kwee D; Miklosi S; Wright G
    Gynecol Oncol; 1986 Mar; 23(3):364-70. PubMed ID: 3514391
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.